Sun Pharma is paying $11.75 billion for Organon, the women’s health and biosimilar maker that Merck spun off. That’s a serious number for a business built on two categories that rarely generate this kind of deal interest.
Organon’s portfolio spans women’s health, a branded commercial franchise, and biosimilars, where competition runs on cost and manufacturing reliability rather than patent exclusivity. They’re different businesses that happen to share a balance sheet. Indian drug giant Sun Pharma is buying both at $11.75 billion.
What does the buyer actually get? A commercial operation in women’s health and biosimilars that Merck decided didn’t belong in its core portfolio. At $11.75 billion, Sun Pharma is betting the right parent company makes all the difference.
The deal is framed as an $11.75 billion portfolio expansion for Sun Pharma. Women’s health and biosimilars are both commercial-stage categories, not speculative pipeline bets. That’s what the $11.75 billion price tag is being paid for.
No close date or per-share price has been disclosed.
Diana Kowalski